Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry

Abstract

PoPH patients are undertreated and show poorer survival than IPAH/FPAH patients. First-line treatment with PAH-targeted therapy was associated with better survival. Presence of ascites was a predictor of mortality.